Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Ann Oncol 28 (suppl 5)(1370P), 490.

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
TLK
2017
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315)

F. Griesinger, W. Eberhardt, N. Marschner, M. Jänicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, M. Sebastian, M. Thomas, 2017.

Ann Oncol. (2017) 28 (suppl_5): v460-v496. https://doi.org/10.1093/annonc/mdx380.086

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2017
Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventinal study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhart, S., Harde, J., Marschner, N., 2017.

Ann Oncol 28 (Supplement 5)(293P), 97. doi:10.1093/annonc/mdx365

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
NABUCCO
2017
Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II).

Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J., 2017.

Ann Oncol 28 (Supplement 5)(8450), v295–v329. doi:10.1093/annonc/mdx371

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
SWITCH II
2017
Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2017.

Ann Oncol 28 (Supplement 5)(899P), 318–319. doi:10.1093/annonc/mdx371

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
PAZOREAL
2017
Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017.

Ann Oncol 28 (Supplement 5)(956P), 340. doi:10.1093/annonc/mdx372

Abstract

Indikation: Other, Sonstige / Veranstaltung: ESMO / Journal: Annals of Oncology
OTILIA
2017
Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017.

Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372

Abstract

Indikation: Other, Sonstige / Veranstaltung: ESMO / Journal: Annals of Oncology
OTILIA
2017
Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice – results from the prospective German TMK cohort study.

N Marschner, T Fietz, J Rauh, A Nusch, U Söling, M Frank, L Kruggel, M Jänicke, 2017.

The Breast, Volume 36, S45 https://doi.org/10.1016/S0960-9776(17)30688-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC4 / Journal:
TMK
2017
Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE).

Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017.

Oncol Res Treat, 40(suppl 3)(P577), 162-163.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
KORALLE
2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017.

BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: BMC Cancer
PASO
2017